Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Efficacy and safety of pola-ICE, with or without rituximab in relapsed/refractory diffuse large B-cell lymphoma: A real-world multicenter study

Huiqiang Huang, Xuan-Ye Zhang, Jicheng Hong, Gao Yan, Peng Liu, Kai Hu, Jingping Pi, Rui Liu, Haoqing Chen, Jialing Zhuang

Blood (2025) 146 (Supplement 1): 7208.

https://doi.org/10.1182/blood-2025-7208

Published: 2025

Journal Articles

Single-cell profiling of natural killer T-cell lymphoma reveals stratified immune features and therapeutic strategies

Qingqing Cai, Yi Cao, Danling Dai, Jinni Wang, Yuchen Zhang, Jie Xiong, Huiqiang Huang, Gao Yan, Yi Xia, Fang Liu, Xinna Gao, Shenrui Bai, Qihua Zou, Wei Li Zhao

Blood (2025) 146 (Supplement 1): 3527.

https://doi.org/10.1182/blood-2025-3527

Published: 2025

Journal Articles

Combination anti-PD1 antibody and rituximab followed by R-CHOP for newly diagnosed DLBCL in elderly patients: Updated results of the phase II TREND trial

Gao Yan, Xue-Ping Li, Xuan-Ye Zhang, Xiaoxiao Wang, Bing BAI, Li-Qin Ping, Qichun Cai, Jia-Ling Zhuang, Huiqiang Huang

Blood (2025) 146 (Supplement 1): 1965.

https://doi.org/10.1182/blood-2025-1965

Published: 2025

Journal Articles

Liposomal mitoxantrone versus chidamide in relapsed/refractory peripheral T-cell lymphoma: Final analysis from the multicenter, prospective randomized phase 3 study

Blood (2025) 146 (Supplement 1): 776.

https://doi.org/10.1182/blood-2025-776

Published: 2025

Journal Articles

Tafasitamab-containing regimens in relapsed/refractory diffuse large B-cell lymphoma: A real-world retrospective case series

Jingyi Xie, Jinshan Gu, Rui Jia, Ge Zhang, Guoming Xie, Jianing Li, Gao Yan, Huiqiang Huang, Qichun Cai

Blood (2025) 146 (Supplement 1): 7226.

https://doi.org/10.1182/blood-2025-7226

Published: 2025

Journal Articles

Golidocitinib, a selective JAK1 kinase inhibitor, in treatment of late thrombocytopenia after CAR-T cell therapy: Case report

Qichun Cai, Jianing Li, Jiasheng Li, Ge Zhang, Feifei Ma, Kailin Ding, Huajuan Ma, Gao Yan, Haijun Wen

Blood (2025) 146 (Supplement 1): 7688.

https://doi.org/10.1182/blood-2025-7688

Published: 2025

Journal Articles

Clinical Features and CSF-Ctdna Characteristics in Extranodal Natural Killer/T‐Cell Lymphoma Patients with Central Nervous System Involvement

Gao Yan, Xue-Ping Li, Xiaoxiao Wang, Xiaoyu Hong, Bing Bai, Xuanye Zhang, Jialing Zhuang, Huiqiang Huang

Blood (2024) 144 (Supplement 1): 3071.

https://doi.org/10.1182/blood-2024-207630

Published: 2024

Journal Articles

Linperlisib in Combination with CHOP for Newly-Diagnosed Peripheral T-Cell Lymphoma: Preliminary Results from the Phase 1b/2 Linch Study

Qingqing Cai, Yi Xia, Huiqiang Huang, Ying Zhao, Fan Yang, Wenning Xu, Hongyan Tong, Chunmei Yang, Xiaojie Fang, Man Nie, Yu Fang, Gao Yan, Xuanye Zhang, Rong Tao, Xiuhua Sun, Xueyi Pan, Tao Wu, Yuchen Zhang, Jun Cai

Blood (2024) 144 (Supplement 1): 6407.

https://doi.org/10.1182/blood-2024-206564

Published: 2024

Journal Articles

Autologous Transplant Consolidation Vs. Immunotherapy Maintanance Therapy in Patients with Relapsed or Refractory NK/T Lymphoma Treated While in Complete Remission

Gao Yan, Xue-Ping Li, Bing Bai, Xiaoxiao Wang, Xuanye Zhang, Huiqiang Huang

Blood (2024) 144 (Supplement 1): 3066.

https://doi.org/10.1182/blood-2024-205253

Published: 2024

Journal Articles

A Phase II Study of Zanubrutinib-Based Induction and Maintenance Therapy in Young and Fit Patients with Untreated Mantle Cell Lymphoma (BRIDGE): An Updated Analysis with Long-Term Follow up

Gao Yan, Qingqing Cai, Zhiming Li, Xiaoxiao Wang, Yi Xia, Xuanye Zhang, He Huang, Bin Bai, Huiqiang Huang

Blood (2023) 142 (Supplement 1): 6147.

https://doi.org/10.1182/blood-2023-181619

Published: 2023

Journal Articles

Novel Chemotherapy-Free Initial Treatment of Rituximab Biosimilar Plus Pegylated Interferon α-2b in Pts with Untreated Advanced Indolent B-Cell Non-Hodgkin's Lymphoma: Results of the Ripple 3-Year Follow-up Study

Gao Yan, Jianqiu Wu, Yunhong Huang, Hui Zhou, Ru Feng, Fei Li, Xue-Ping Li, Xiaoxiao Wang, Bing Bai, Yu-Hua Huang, Haixia He, Liqin Ping, Yanxia He, Cheng Huang, Jibin Li, Jiaying Mao, Huiqiang Huang

Blood (2023) 142 (Supplement 1): 4411.

https://doi.org/10.1182/blood-2023-186099

Published: 2023

Journal Articles

PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r ENKTL): Updates of the Phase Ib/II Scent Study

Gao Yan, Liling Zhang, Wenyu Li, Xu Wei, Ru Feng, Xue-Ping Li, Yu Chen, Huijing Wu, Xiaoxiao Wang, Bing Bai, Huiqiang Huang

Blood (2023) 142 (Supplement 1): 1689.

https://doi.org/10.1182/blood-2023-186252

Published: 2023

Journal Articles

Combination Anti-PD1 Antibody and Rituximab Followed By R-CHOP for Elderly Patients with Newly Diagnosed DLBCL: Analysis of the Phase II TREND Trial

Gao Yan, Xiaoxiao Wang, Bing Bai, Xue-Ping Li, Suxia Lin, Yanxia He, Liqin Ping, Cheng Huang, Jibin Li, Jiaying Mao, Huiqiang Huang

Blood (2022) 140 (Supplement 1): 3737–3738.

https://doi.org/10.1182/blood-2022-166936

Published: 2022

Journal Articles

Sintilimab Plus P-Gemox (Pegaspargase, Gemcitabine and Oxaliplatin) Regimen for Newly-Diagnosed Advanced, Extranodal Natural Killer/T Cell Lymphoma, Nasal Type: A Multicenter, Phase 2 Cohort of the Open-Label Spirit Study

Qingqing Cai, Panpan Liu, Yi Xia, Jun Cai, Huiqiang Huang, Zhiming Li, Hui Zhou, Yajun Li, Hanyu Wang, Ying Huang, Gao Yan, Xueyi Pan

Blood (2022) 140 (Supplement 1): 2299–2301.

https://doi.org/10.1182/blood-2022-168457

Published: 2022

Journal Articles

DNA-Demethylating Agents Combined with Anti-PD-1 Inhibitors Showed Activity in Patients with Relapsed or Refractory Extranodal NK/T Cell Lymphoma Who Have Failed Immunotherapy: An Exploratory Study

Gao Yan, Cheng Huang, Xue-Ping Li, Xiaoxiao Wang, Bing Bai, Yanxia He, Liqin Ping, Huiqiang Huang

Blood (2022) 140 (Supplement 1): 9393–9394.

https://doi.org/10.1182/blood-2022-165874

Published: 2022

Journal Articles

Combination of Mitoxantrone Hydrochloride Liposome with Cyclophosphamide, Vincristine and Prednisone (CMOP) in Treatment-Naïve Patients with Peripheral T-Cell Lymphoma: A Multicenter, Open-Label, Single-Arm, Phase Ib Clinical Trial

Hui-Qiang Huang, Gao Yan, Ming Jiang, Lihong Liu, Qing Xiao, Yufu Li, Hui Zhou, Jianfei Xue, Dong Wang, Dapeng Xie, Honglian Li, Peng Wang

Blood (2022) 140 (Supplement 1): 3762–3763.

https://doi.org/10.1182/blood-2022-163343

Published: 2022

Journal Articles

Prophylaxis of Neutropenia with Mecapegfilgrastim in Patients with Hematologic Malignancies

Hui-qiang Huang, Zengjun Li, Gang Cheng, Gao Yan, Zhihua Yao, Guifang Zhang, Xiaoguang Wang, Zhengxiang Han, Yong Chen, Haijiao Yan, Weie Zheng, Jun Yan, Yulan Gu, Zhangxia Ren, Rusen Zhao, Ningling Zhang, Jun Ma

Blood (2021) 138 (Supplement 1): 4569.

https://doi.org/10.1182/blood-2021-149884

Published: 2021

Journal Articles

Novel Induction Therapy for Newly Diagnosed Extranodal Natural Killer/T Cell Lymphoma (ENKTL) Treated By Anti-PD-1 Antibody Plus Histone Deacetylase Inhibitor Followed By P-GemOx Regimen

Gao Yan, Yujing Zhang, Xiaoxiao Wang, Bing Bai, Yuhua Huang, Haixia He, Liqin Ping, Yanxia He, Cheng Huang, Jibin Li, Jiaying Mao, Huiqiang Huang

Blood (2021) 138 (Supplement 1): 137.

https://doi.org/10.1182/blood-2021-147169

Published: 2021

Journal Articles

Rituximab Biosimilar Combined with Pegylated Interferon α-2b in Patients with Untreated Advanced Indolent B-Cell Non-Hodgkin's Lymphoma: Preliminary Results from a Multicenter, Single-Arm, Phase II Study

Gao Yan, Jianqiu Wu, Yunhong Huang, Hui Zhou, Ru Feng, Li Fei, Xiaoxiao Wang, Bing Bai, Yuhua Huang, Haixia He, Liqin Ping, Yanxia He, Cheng Huang, Jibin Li, Jiaying Mao, Huiqiang Huang

Blood (2021) 138 (Supplement 1): 1359.

https://doi.org/10.1182/blood-2021-152018

Published: 2021

Journal Articles

Safety and Efficacy of Mitoxantrone Hydrochloride Liposome in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma and Extranodal NK/T-Cell Lymphoma: A Multicenter, Single-Arm, Open-Label, Phase 2 Clinical Trial

Blood (2019) 134 (Supplement_1): 2838.

https://doi.org/10.1182/blood-2019-126481

Published: 2019

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Efficacy and safety of pola-ICE, with or without rituximab in relapsed/refractory diffuse large B-cell lymphoma: A real-world multicenter study

Single-cell profiling of natural killer T-cell lymphoma reveals stratified immune features and therapeutic strategies

Combination anti-PD1 antibody and rituximab followed by R-CHOP for newly diagnosed DLBCL in elderly patients: Updated results of the phase II TREND trial

Liposomal mitoxantrone versus chidamide in relapsed/refractory peripheral T-cell lymphoma: Final analysis from the multicenter, prospective randomized phase 3 study

Tafasitamab-containing regimens in relapsed/refractory diffuse large B-cell lymphoma: A real-world retrospective case series

Golidocitinib, a selective JAK1 kinase inhibitor, in treatment of late thrombocytopenia after CAR-T cell therapy: Case report

Clinical Features and CSF-Ctdna Characteristics in Extranodal Natural Killer/T‐Cell Lymphoma Patients with Central Nervous System Involvement

Linperlisib in Combination with CHOP for Newly-Diagnosed Peripheral T-Cell Lymphoma: Preliminary Results from the Phase 1b/2 Linch Study

Autologous Transplant Consolidation Vs. Immunotherapy Maintanance Therapy in Patients with Relapsed or Refractory NK/T Lymphoma Treated While in Complete Remission

A Phase II Study of Zanubrutinib-Based Induction and Maintenance Therapy in Young and Fit Patients with Untreated Mantle Cell Lymphoma (BRIDGE): An Updated Analysis with Long-Term Follow up

Novel Chemotherapy-Free Initial Treatment of Rituximab Biosimilar Plus Pegylated Interferon α-2b in Pts with Untreated Advanced Indolent B-Cell Non-Hodgkin's Lymphoma: Results of the Ripple 3-Year Follow-up Study

PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r ENKTL): Updates of the Phase Ib/II Scent Study

Combination Anti-PD1 Antibody and Rituximab Followed By R-CHOP for Elderly Patients with Newly Diagnosed DLBCL: Analysis of the Phase II TREND Trial

Sintilimab Plus P-Gemox (Pegaspargase, Gemcitabine and Oxaliplatin) Regimen for Newly-Diagnosed Advanced, Extranodal Natural Killer/T Cell Lymphoma, Nasal Type: A Multicenter, Phase 2 Cohort of the Open-Label Spirit Study

DNA-Demethylating Agents Combined with Anti-PD-1 Inhibitors Showed Activity in Patients with Relapsed or Refractory Extranodal NK/T Cell Lymphoma Who Have Failed Immunotherapy: An Exploratory Study

Combination of Mitoxantrone Hydrochloride Liposome with Cyclophosphamide, Vincristine and Prednisone (CMOP) in Treatment-Naïve Patients with Peripheral T-Cell Lymphoma: A Multicenter, Open-Label, Single-Arm, Phase Ib Clinical Trial

Prophylaxis of Neutropenia with Mecapegfilgrastim in Patients with Hematologic Malignancies

Novel Induction Therapy for Newly Diagnosed Extranodal Natural Killer/T Cell Lymphoma (ENKTL) Treated By Anti-PD-1 Antibody Plus Histone Deacetylase Inhibitor Followed By P-GemOx Regimen

Rituximab Biosimilar Combined with Pegylated Interferon α-2b in Patients with Untreated Advanced Indolent B-Cell Non-Hodgkin's Lymphoma: Preliminary Results from a Multicenter, Single-Arm, Phase II Study

Safety and Efficacy of Mitoxantrone Hydrochloride Liposome in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma and Extranodal NK/T-Cell Lymphoma: A Multicenter, Single-Arm, Open-Label, Phase 2 Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only